Videos

Data suggested that most patients do not have a preference on the gender of the urologist who is providing their vasectomy care.

Jason M. Hafron, MD, CMO, touches on the growing shift toward biomarker-driven therapy in advanced prostate cancer.

Joshua J. Meeks, MD, PhD, highlights that collaboration between urologists and medical oncologists has become essential.

Jason M. Hafron, MD, recaps noteworthy prostate cancer research from ESMO 2025.

Stacy Loeb, MD, discussed key takeaways from the European Randomized Study of Screening for Prostate Cancer.

Stacy Loeb, MD, shares key takeaways from her LUGPA 2025 session, “Current state of prostate cancer screening.”

Beyond radioligands, Henderson points to a number of novel therapeutic categories under investigation.

Henderson emphasized the evolving role of advanced biomarkers in refining prostate cancer risk assessment beyond traditional PSA testing

Andrew W. Hahn, MD, highlights safety and tolerability data on lenvatinib/everolimus vs cabozantinib for metastatic ccRCC.

An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer.

Celeste Kirschner, CAE, MHSA, outlines the most pressing challenges facing independent urology practices today.

Collins stresses the oncological importance of local control, as local recurrences can lead to a "second wave of metastatic disease" that can ultimately cause death.

Suzanne B. Merrill, MD, FACS, discussed the feasibility of integrating immune checkpoint inhibitors into clinical practice for NMIBC, particularly in the community setting.

Freedland reviews enzalutamide’s long-term safety profile, drawing from the EMBARK, ARCHES, and ENZAMET trials. He explains strategies for managing adverse events, balancing efficacy with tolerability, and comparing safety outcomes across other androgen receptor pathway inhibitors to help clinicians personalize care.

Aaron R. Hansen, BSc, MBBS, FRACP, highlights key findings from the theraPb trial, exploring the safety and preliminary efficacy of ADVC001 in mCRPC.

Ravi D. Chauhan, MD, FACS, outlines the practical considerations for administering nadofaragene in clinical practice.

Panelists discuss how prednisone coadministration with abiraterone impacts tolerability and monitoring in patients with cardiometabolic comorbidities, guiding safer, personalized treatment choices in mCSPC.

Panelists discuss how real-world evidence comparing apalutamide and abiraterone, including the impact of prednisone use, informs balanced and patient-specific first-line treatment choices.

Jonathan Henderson, MD, recaps his LUGPA 2025 session, “Lessons Learned: Avoiding Pitfalls in Urology Practice Management.”

Safety outcomes were favorable: cystectomy-free survival was 94%, overall survival was 100%, and only 1 patient progressed to muscle-invasive disease.

Marc Machaalani, MD, shares data on soluble MAdCAM-1 as a predictive biomarker in metastatic renal cell carcinoma.

Panelists discuss how the future of IsoPSA and similar biomarkers depends on data validation, payer support, and integration into clinical guidelines.

Panelists discuss how IsoPSA strengthens biopsy discussions by providing objective data that supports patient confidence in shared decision-making.

The final segment discusses operational and logistical impacts, including workflow efficiency, staff training, and reimbursement considerations for subcutaneous immunotherapy.

Sisters Amy Pearlman, MD, and Michelle Pearlman, MD, provide an overview of their shared practice, Prime Institute.

Ronney Abaza, MD, predicts the transformative impact that AI will have in robotic surgery.

In determining the best treatment, urologist Arpeet Shah, MD, stresses the importance of thorough diagnostics.

Brooke Edwards, MD, highlights key takeaways from her LUGPA 2025 session, "Transforming your ASC."

Looking forward, Meeks said he sees nadofaragene firadenovec as a promising addition to the NMIBC treatment landscape.

Martin M. Miner, MD, highlights key findings from TRAVERSE and the T4DM study.